Keywords
Clinical diagnosis
Pituitary adenoma
Pituitary function tests
Diagnostic imaging
Therapeutics
Follow up care
How to Cite
Abstract
Background: Cushing's disease is a rare disease in the general population, with an insidious clinical evolution, which creates a for timely diagnosis based on clinical suspicion. Taking into account the origin of the disease given by the presence of a pituitary tumor that secretes adrenocorticotropic hormone (ACTH); treatment should be aimed at achieving biochemical control and resection of the tumor mass. Patient follow-up aimed at monitoring the control of the disease and early detection of the development of comorbidities is a key aspect in the proper management of the disease.
Purpose: To define criteria for the diagnosis, treatment and follow-up of Cushing's disease in Colombian patients.
Methodology: A modified Delphi-type consensus was drawn up with a multidisciplinary group of experts in the management of patients with Cushing's disease (endocrinologists and neurosurgeons) and the consensus was directed by a clinical pharmacologist. The results were analyzed and discussed. Based on the achievement of consensus, a series of recommendations are presented in the different sections of Cushing's disease.
Results: Recommendations based on expert opinion were generated for the approach to the patient with Cushing's disease, including aspects of clinical suspicion; biochemical and imaging diagnosis; treatment by surgical intervention; pharmacological treatment alternatives; radiosurgery and patient follow-up.
Conclusions: In Colombia it is important to strengthen medical knowledge from primary care to specialists with high expertise in issues such as the correct diagnosis, management and follow-up of the patient with Cushing's disease to achieve early detection of the disease and reduce the progression of the diseases. associated comorbidities.
References
Findling J, Raff H. Cushing’s syndrome: Important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91(10):3746-53. https://doi.org/10.1210/jc.2006-0997
Aron DC. Cushing’s Syndrome from Bedside to Bench and Back: A Historical Perspective. Endocrinol Metab Clin North Am. 2005 jun.;34(2):257-69. https://doi.org/10.1016/j.ecl.2005.01.011
Chaudhry HS, Singh G. Cushing Syndrome. Treasure Island, Florida: StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK470218/
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. The Lancet. 2006 my.;367(9522):1605-17. https://doi.org/10.1016/S0140-6736(06)68699-6
Jeong Y, Han H, Lee H, Yang J, Jeong J, Ki Choi M, et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat. 2016;48(4):1429-37. https://doi.org/10.4143/crt.2015.464
Hwang J, Weiss R. Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102. https://doi.org/10.1002/dmrr.2486
Araya AV, Liberman C, Munizaga C, Pineda P, Barberán M, Cordero F, et al. Combination of High Prevalence Sign/Symptom Pairs: An Approach to the Diagnosis of Cushing’s Syndrome. En: Adrenal Glands - The Current Stage and New Perspectives of Diseases and Treatment [Working Title]. IntechOpen; 2022 [citado 2023, agosto 8]. Disponible en: https://www.intechopen.com/online-first/83273
Nieman LK. Diagnosis of Cushing’s Syndrome in the Modern Era. Endocrinol Metab Clin North Am. 2018 jun,;47(2):259-73. https://doi.org/10.1016/j.ecl.2018.02.001
Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s Syndrome. Endocrinol Metab Clin North Am. 2008 mzo.;37(1):135-49. https://doi.org/10.1016/j.ecl.2007.10.010
Chabre O. The difficulties of pseudo-Cushing’s syndrome (or “non-neoplastic hypercortisolism”). Ann Endocrinol. 2018 jun.;79(3):138-45. https://doi.org/10.1016/j.ando.2018.04.017
Santos S, Santos E, Gaztambide S, Salvador J. Diagnóstico y diagnóstico diferencial del síndrome de Cushing. Endocrinol Nutr. 2009 febr.;56(2):71-84. https://doi.org/10.1016/S1575-0922(09)70555-8
Pecori Giraldi F. PseudoCushing: why a clinical challenge? J Endocrinol Invest. 2015 oct.;38(10):1137-9. https://doi.org/10.1007/s40618-015-0296-5
Zada G. Diagnosis and Multimodality Management of Cushing’s Disease: A Practical Review. Int J Endocrinol. 2013;2013:1-7. https://doi.org/10.1155/2013/893781
Tritos N, Biller B, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7(5):279-89. https://doi.org/10.1038/nrendo.2011.12
Raff H, Sharma S, Nieman L. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing’s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014;4(2):739-69. https://doi.org/10.1002/cphy.c130035
Clayton RN. Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality. J Neuroendocrinol. 2022 ag.;34(8). https://onlinelibrary.wiley.com/doi/10.1111/jne.13175
García Valdés M, Suárez Marín M. El método Delphi para la consulta a expertos en la investigación científica. Rev Cuba Salud Pública. 2013;39(2):253-67.
Joint Commission international. Accreditation standards for Hospitals; 2021. https://www.jointcommissioninternational.org/-/media/jci/jci-documents/accreditation/hospital-and-amc/jci-errata-standards-only_7th-ed-hospital.pdf
Matas A. Diseño del formato de escalas tipo Likert: un estado de la cuestión. Rev Electrónica Investig Educ. 2018 febr. 9;20(1):38. https://doi.org/10.24320/redie.2018.20.1.1347
Patrão Neves M. Consensus. En: ten Have H, editor. Encyclopedia of Global Bioethics. Cham: Springer International Publishing; 2015 [citado 14 de abril de 2023]. p. 1-9. Disponible en: https://link.springer.com/10.1007/978-3-319-05544-2_119-1
Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM Levels of Evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine. [Internet]. Disponible en: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
Castinetti F, Morange I, Conte-Devolx B, Brue T. Cushing’s disease. Orphanet J Rare Dis. 2012;7(1):41. https://doi.org/10.1186/1750-1172-7-41
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 ag.;100(8):2807-31. https://doi.org/10.1210/jc.2015-1818
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021 dic.;9(12):847-75. https://doi.org/10.1016/S2213-8587(21)00235-7
Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al. Time to Diagnosis in Cushing’s Syndrome: A Meta-Analysis Based on 5367 Patients. J Clin Endocrinol Metab. 2020 mzo. 1;105(3):e12-22. https://doi.org/10.1210/clinem/dgz136
Pinzon-Tovar A, Oviedo-Cali M, Jimenez-Salazar S, Mendez H, Buitrago-Toro K. Hipercortisolismo severo e hipocalemia recurrente. Acta Méd Perú. 2022 ag.;39(2). https://amp.cmp.org.pe/index.php/AMP/article/view/2363
Gutiérrez-Restrepo J, Román-González A. Síndrome de Cushing ectópico: revisión de la literatura. Rev Colomb Cancerol. 2016 oct.;20(4):175-82. https://doi.org/10.1016/j.rccan.2016.03.001
Syro L, Rotondo F, Kovacs K, Korbonits M. Clinicopathologic features of familial pituitary adenomas. Diagn Histopathol. 2016;22(3):85-91. https://doi.org/10.1016/j.mpdhp.2016.02.004
García Botina HD, Lara Botina DR, Mauricio Sánchez F, Román González A. Presentación de tres casos y revisión en la literatura: Síndrome de Cushing. Arch Med Manizales. 2017 dic. 6;17(2):415-24. https://doi.org/10.30554/archmed.17.2.2403.2017
Santos S, Santos E, Gaztambide S, Salvador J. Diagnóstico y diagnóstico diferencial del síndrome de Cushing. Endocrinol Nutr. 2009 febr.;56(2):71-84. https://doi.org/10.1016/S1575-0922(09)70555-8
Galm BP, Qiao N, Klibanski A, Biller BM, Tritos NA. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2020 jun. 1;105(6):2081-94. https://doi.org/10.1210/clinem/dgaa105
Savas M, Mehta S, Agrawal N, van Rossum EF, Feelders RA. Approach to the Patient: Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2022 nov. 23;107(11):3162-74. https://doi.org/10.1210/clinem/dgac492
Espinosa de los Monteros-Sánchez A. Consenso en el diagnóstico y tratamiento del síndrome de Cushing. Rev Endocrinol Nutr. 2007;15(4):S3-12.
Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing’s Disease. Clin Med Insights Oncol. 2012 en.;6:CMO.S6198. https://doi.org/10.4137/CMO.S6198
Honegger J, Nasi?Kordhishti I. Surgery and perioperative management of patients with Cushing’s disease. J Neuroendocrinol. 2022 ag.;34(8). https://onlinelibrary.wiley.com/doi/10.1111/jne.13177
Araujo-Castro M, Pascual-Corrales E, Martínez San Millan JS, Rebolleda G, Pian H, Ruz-Caracuel I, et al. Postoperative management of patients with pituitary tumors submitted to pituitary surgery. Experience of a Spanish Pituitary Tumor Center of Excellence. Endocrine. 2020 jul.;69(1):5-17. https://doi.org/10.1007/s12020-020-02247-y
Feelders RA, Hofland LJ. Medical Treatment of Cushing’s Disease. J Clin Endocrinol Metab. 2013 febr.;98(2):425-38. https://doi.org/10.1210/jc.2012-3126
Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, et al. Medical Treatment of Cushing’s Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol. 2020 dic. 8;11:648. https://doi.org/10.3389/fendo.2020.00648
Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol. 2019 abr.;7(4):300-12. https://doi.org/10.1016/S2213-8587(18)30155-4
Hughes JD, Young WF, Chang AY, Link MJ, Garces YI, Laack N, et al. 209 Radiosurgical Management of Patients With Persistent or Recurrent Cushing’s Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience. Neurosurgery. 2018 sept. 1;65(supl. 1):118. https://doi.org/10.1093/neuros/nyy303.209
Pence A, McGrath M, Lee SL, Raines DE. Pharmacological management of severe Cushing’s syndrome: the role of etomidate. Ther Adv Endocrinol Metab. 2022 en.;13:204201882110585. https://doi.org/10.1177/20420188211058583
Santos A, Resmini E, Martínez Momblán MA, Valassi E, Martel L, Webb SM. Quality of Life in Patients With Cushing’s Disease. Front Endocrinol. 2019 dic. 11;10:862. https://doi.org/10.3389/fendo.2019.00862
Serban AL, Del Sindaco G, Sala E, Carosi G, Indirli R, Rodari G, et al. Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. J Endocrinol Invest. 2020 my.;43(5):631-9. https://doi.org/10.1007/s40618-019-01151-1
Le Marc’hadour P, Muller M, Albarel F, Coulon AL, Morange I, Martinie M, et al. Postoperative follow-up of Cushing’s disease using cortisol, desmopressin and coupled dexamethasone-desmopressin tests: a head-to-head comparison. Clin Endocrinol (Oxf). 2015 ag.;83(2):216-22. https://doi.org/10.1111/cen.12739
Guignat L, Bertherat J. Long?term follow?up and predictors of recurrence of Cushing’s disease. J Neuroendocrinol. 2022 ag.;34(8). https://onlinelibrary.wiley.com/doi/10.1111/jne.13186
Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing’s disease. Pituitary. 2015 abr.;18(2):188-94. https://doi.org/10.1007/s11102-015-0645-6
Schernthaner-Reiter MH, Siess C, Gessl A, Scheuba C, Wolfsberger S, Riss P, et al. Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission. Endocrine. 2019 abr.;64(1):157-68. https://doi.org/10.1007/s12020-018-1819-6
Ferraù F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol. 2015 oct.;173(4):M133-57. https://doi.org/10.1530/EJE-15-0354
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo